# Antimicrobial Susceptibility Report January 1, 2023 to December 31, 2023 Erie St. Clair LTC (Excluding Hospitals)

# **Urinary Tract Pathogens (in Order of Frequency) - % Susceptible**

Organism	Number of Isolates	Amox clavulanic	Ampicillin	Cefazolin (1)	Ceftazidime	Ceftriaxone	Ciprofloxacin	Fosfomycin	Gentamicin	Meropenem	Nitrofurantoin	Trimethoprim- Sulfamethoxazole
E. coli ^	546	70	52	75		78	51	96	94	100	94	79
Klebsiella pneumoniae *	153	82		82		84	83		97	100	65	84
Enterococcus species ^^^^	145											
Proteus mirabilis +	118	91	69	84		95	64		92	100		77
Pseudomonas aeruginosa	58				95		86					
Group B Streptococcus ^^	<30											

### **Organism Notes:**

\* Includes ESBL and AMP-C isolates (15.7% of total Klebsiella pneumoniae isolates identified as ESBL and AMP-C).

^ Includes ESBL and AMP-C isolates (21.4% of total E.coli isolates identified as ESBL and AMP-C ).

M This isolate is predictably susceptible to Penicillin.

Clindamycin, Trimethoprim/Sulfamethoxazole and all Cephalosporins are ineffective against Enterococcus species. Enterococcus isolates recovered from urine are generally susceptible to amoxicillin and nitrofurantoin. Susceptibility to Amoxicillin is 97.0% and to Nitrofurantoin is 95.2%

+ Includes ESBL and AMP-C isolates ( 5.1% of total Proteus mirabilis isolates identified as ESBL and AMP-C ).

### Antibiotic Notes:

(1) Cefazolin interpretation predicts results for Cephalexin (Keflex) in accordance with CLSI standards for urinary sites only (not systemic).

## All Other Specimen Types excluding (Urines and Surveillance) - Organisms in Order of **Frequency - % Susceptible**

Organism	Number of Isolates	Cefazolin	Ceftazidime	Ciprofloxacin	Clindamycin	Cloxacillin	Erythromycin	Tetracycline (2)	Trimethoprim- Sulfamethoxazole
Staphylococcus aureus ^^^	306	<b>67</b> n:273			58 n:273	<b>67</b> n:273	<b>45</b> n:273	<b>99</b> n:272	<b>99</b> n:273
Pseudomonas aeruginosa	135		89	76					
Group B Streptococcus ^^	31								

### Organism Notes:

^ This isolate is predictably susceptible to Penicillin.

MRSA is resistant to all B-Lactams (penicillins, cephalosporins, B-lactam/B-lactamase inhibitor combinations, and carbapenems). MRSA constitutes 31.7% of total Staphylococcus aureus isolates identified.

### **Antibiotic Notes:**

(2) Organisms that are susceptible to Tetracycline are also considered susceptible to Doxycycline.

#### **General Notes:**

Antibiogram results, patient risk factors for resistant organisms, and resistance epidemiology should be considered together to help guide empiric treatment of initial infections. Treatment should be re-evaluated as additional information from culture and sensitivity become available.

Calculation of results based on first isolate per patient.

